Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1994 Apr;71(4):349–353. doi: 10.1136/hrt.71.4.349

Randomised placebo controlled double blind study of two low dose aprotinin regimens in cardiac surgery.

C R Bailey 1, A K Wielogorski 1
PMCID: PMC483684  PMID: 7515260

Abstract

OBJECTIVE--To determine whether two low dose aprotinin regimens produce clinically significant reductions in postoperative blood loss compared with a control group. DESIGN--A randomised double blind placebo controlled study. SETTING--A regional cardiothoracic unit in London. PATIENTS--79 patients were consecutively allocated to one of three groups. All patients had primary elective surgery with standard anaesthetic and surgical techniques, and no patients were withdrawn from the study. INTERVENTIONS--Group K patients (n = 27) received aprotinin (10(6) kallikrein inactivator units (KIU) into the pump prime whereas group L patients (n = 27) received an intravenous bolus of aprotinin (0.5 x 10(6) KIU) after induction of anaesthesia and 10(6) KIU was added to the pump prime. A third group (group J, n = 25) received 0.9% saline placebo. MAIN OUTCOME MEASURES--After insertion of the chest drains at the end of cardiopulmonary bypass, blood losses were measured hourly until the drains were removed 18 to 24 h later. Total haemoglobin loss into the chest drains was calculated. RESULTS--Both aprotinin treated groups showed significantly less postoperative blood loss than controls (medians: group K, 400 ml; group L, 400 ml; v controls 780 ml; p < 0.001) and there was even less measured postoperative haemoglobin loss within the chest drains in both the aprotinin treated groups than in the controls (medians: group K, 16 g; group L, 19 g; v controls, 47 g; p < 0.001). CONCLUSION--In primary cardiac surgery the dose of aprotinin may be reduced by about 80% from the recommended high dose schedule and still significantly reduce postoperative blood loss compared with placebo.

Full text

PDF
349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bidstrup B. P., Royston D., Sapsford R. N., Taylor K. M. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989 Mar;97(3):364–372. [PubMed] [Google Scholar]
  2. Blauhut B., Gross C., Necek S., Doran J. E., Späth P., Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991 Jun;101(6):958–967. [PubMed] [Google Scholar]
  3. Böhrer H., Fleischer F., Lang J., Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth. 1990 Apr;4(2):222–225. doi: 10.1016/0888-6296(90)90241-7. [DOI] [PubMed] [Google Scholar]
  4. Carrel T., Bauer E., Laske A., von Segesser L., Turina M. Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991 Nov;102(5):801–802. [PubMed] [Google Scholar]
  5. Dietrich W., Spannagl M., Jochum M., Wendt P., Schramm W., Barankay A., Sebening F., Richter J. A. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 1990 Dec;73(6):1119–1126. doi: 10.1097/00000542-199012000-00009. [DOI] [PubMed] [Google Scholar]
  6. Fraedrich G., Weber C., Bernard C., Hettwer A., Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin--preliminary results. Thorac Cardiovasc Surg. 1989 Apr;37(2):89–91. doi: 10.1055/s-2007-1013914. [DOI] [PubMed] [Google Scholar]
  7. Havel M., Teufelsbauer H., Knöbl P., Dalmatiner R., Jaksch P., Zwölfer W., Müller M., Vukovich T. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg. 1991 Jun;101(6):968–972. [PubMed] [Google Scholar]
  8. Locatelli A., Ceriana P., Maurelli M., Bertollo D., Bianchi T., Mazza M. P., Chiaudani G., Pagnin A. Aprotinin in cardiac surgery. Lancet. 1991 Jul 27;338(8761):254–254. doi: 10.1016/0140-6736(91)90394-5. [DOI] [PubMed] [Google Scholar]
  9. Lu H., Soria C., Commin P. L., Soria J., Piwnica A., Schumann F., Regnier O., Legrand Y., Caen J. P. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost. 1991 Dec 2;66(6):633–637. [PubMed] [Google Scholar]
  10. Royston D., Bidstrup B. P., Taylor K. M., Sapsford R. N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987 Dec 5;2(8571):1289–1291. doi: 10.1016/s0140-6736(87)91190-1. [DOI] [PubMed] [Google Scholar]
  11. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 1992 Feb;6(1):76–100. doi: 10.1016/1053-0770(91)90052-u. [DOI] [PubMed] [Google Scholar]
  12. de Smet A. A., Joen M. C., van Oeveren W., Roozendaal K. J., Harder M. P., Eijsman L., Wildevuur C. R. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg. 1990 Oct;100(4):520–527. [PubMed] [Google Scholar]
  13. van Oeveren W., Harder M. P., Roozendaal K. J., Eijsman L., Wildevuur C. R. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990 May;99(5):788–797. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES